Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 2.6%

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) dropped 2.6% on Tuesday . The company traded as low as $2.96 and last traded at $2.98. Approximately 263,309 shares were traded during trading, a decline of 90% from the average daily volume of 2,767,350 shares. The stock had previously closed at $3.06.

Wall Street Analyst Weigh In

TSHA has been the subject of a number of research analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Chardan Capital boosted their price target on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, March 21st. Needham & Company LLC boosted their price target on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Wednesday, March 20th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $6.57.

Taysha Gene Therapies Trading Up 3.6 %

The company has a 50-day moving average of $2.15 and a 200-day moving average of $2.13. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.08 and a current ratio of 4.08.

Institutional Trading of Taysha Gene Therapies

Large investors have recently added to or reduced their stakes in the company. Capital Investment Advisors LLC purchased a new stake in Taysha Gene Therapies during the 3rd quarter valued at about $32,000. AQR Capital Management LLC purchased a new stake in Taysha Gene Therapies during the 2nd quarter valued at about $38,000. Howard Capital Management Inc. purchased a new stake in Taysha Gene Therapies during the 4th quarter valued at about $25,000. Maven Securities LTD purchased a new stake in shares of Taysha Gene Therapies in the fourth quarter worth about $34,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Taysha Gene Therapies in the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.